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Abstract
Background: Angiotensin-converting enzyme (ACE) inhibitors are widely prescribed for patients with diabetes as a
nephroprotector drug or to treat hypertension. Generally they are safe for clinical practice, but the relationship
between these drugs and angioedema is known. The exact mechanism for ACE inhibitors-induced angioedema is
not clear and it is still a matter of discussion.
Case Report: We reported a case of a 23-year-old black female with an 11 year history of type 1 diabetes,
regularly monitored in the department of diabetes, in use of 0,98 UI/kg/day of human insulin, which presented an
allergic reaction 24 h after ramipril use. The drug had been prescribed to treat diabetic nephropathy. There was no
previous history of drug induced or alimentary allergy. The patient was instructed to discontinue the use of
ramipril and oral antihistaminic drug and topical corticosteroid were prescribed. Skin biopsies were performed and
confirmed the clinical hypothesis of pharmacodermy. The evaluation of ACE polymorphism identified DD genotype.
Six months after the withdrawal of ramipril the patient was prescribed the angiotensin-II receptor blocker (ARB)
losartan as nephroprotector. She remained well without adverse reactions.
Conclusions: ACE inhibitors-induced angioedema is uncommon and the clinical presentation is variable with lips,
tongue, oropharinge, and larynge as the most common locations. The presence of angioedema during treatment
requires the immediate cessation of treatment due to the risk of possible severe complications. The case reported
presented moderate symptoms, with the development of early onset edema in uncommon regions. ACE DD
genotype had been associated with angioedema-ACE inhibitors induced. In patients who have experienced ACE
inhibitor-related angioedema, ARB should be used cautiously used. However in the case of our patient, the
prescription of losartan as nefroprotector did not result in any recurrent adverse effect.
Background
Angiotensin-converting enzyme (ACE) inhibitors are
widely prescribed for patients with diabetes as a nefro-
protector drug or to treat hypertension. Generally, they
are safe for clinical practice, but the relationship
between these drugs and angioedema is known.
We report a case of a young female diagnosed with
type 1 diabetes that developed angioedema and drug
reaction after administration of ramipril.
Case Report
A 23-year-old black female with an 11 year history of
type 1 diabetes, was admitted to the hospital 5 days
after the appearance of pruriginous erythemato-vesi-
culo-papulous eruptive lesions in abdomen with later
generalization. Some lesions presented local bleeding
and she noted swelling of the face and ears. There was
no history of drug induced or alimentary allergy. She
was using 0,98 UI/Kg/day of human insulin and had
started the use of the ACE ramipril 5 mg 24 hours
before the symptoms occurred (prescribed to treat dia-
betic nephropathy). The patient presented normal
renal function, weight and blood pressure levels. The
evaluation of ACE polymorphism identified DD
genotype.
On admission she was afebrile, normotensive and had
no respiratory distress. On examination there were
erythemato-papular lesions in abdomen and in posterior
region of the thighs, some confluents and with vesicles.
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She presented periorbital swelling and erythematosus-
swelling lesions in ears.
A clinical angioedema and an allergic reaction to
ramipril were suspected. The patient was instructed to
discontinue the use of ramipril, and oral antihistaminic
drug and topical mometasone furoate were prescribed.
Skin biopsies were performed in abdominal lesions.
The lesion regression was gradual and after 3 months
there was residual hypercromy in previously injured site.
Later the histopathological findings confirmed the
clinical hypothesis of pharmacodermy related to ramipril
that manifested as erythemato-papular lesions and
angioedema.
Six months after the withdrawal of ramipril the patient
was prescribed the angiotensin-II receptor blocker losar-
tan 25 mg OP as nephroprotector. She remained well
without adverse reactions.
Discussion
Angiotensin converting enzyme (ACE) inhibitors have
been widely used in the treatment of cardiovascular and
renal diseases. They are known to cause dry cough,
hypotension, hyperkalemia and angioedema as adverse
effects [1,2].
Diabetic nephropathy is a common cause of kidney
failure and it is important to treat correctly. Diet and
drugs that block the renin-angiotensin-aldosterone sys-
tem are prescribed in early stage [3]. On advanced stage,
dyalisis and renal transplantation are treatment options.
Recent publication showed that type 1 diabetic patients
show higher survival rates after transplant in compari-
son to the dialysis therapy [4].
The case reports a young, black female diagnosed with
type 1 diabetes who developed angioedema and prurigi-
nous reaction 24 hours after starting ramipril use to
treat diabetic nephropathy.
ACE inhibitors-induced angioedema is uncommon. The
incidence is very low (0,1 - 0,2%), but it is quite underesti-
mated because of poorly recognized presentation, espe-
cially because of its late onset [5]. It most commonly
affects African Americans, women [6,7] and smokers [7].
The onset of angioedema is variable; it can occur
within the first 24 hours of ACE inhibitors use, however
weeks, months and years have also been described.
These variable temporal relationships between drug
administration and adverse effects can contribute to a
failure in recognizing the association and discontinua-
tion of ACE inhibitors [7].
The ACE inhibitors can induce urticariform reactions,
bullous lesions and phototoxic reactions, in particular
captopril which contains a thiol group [8] as with angioe-
dema, usually without associated urticaria [8]. Some
authors reviewing charts of patients presenting angioe-
dema to an emergency department have observed that
pruritus was noted only in patients with angioedema not
related to the use of ACE inhibitors [9]. The most com-
mon locations for angioedema-ACE inhibitors induced
are lips, tongue, oropharinge, and larynge. In the last case
the patient could eventually need intubation [10]. Others
drugs commonly prescribed for diabetic patients may
also cause cutaneous reaction (table 1).
The case reported presented moderate symptoms,
with the development of edema in uncommon regions,
such as the external ear and eyelids, besides the pre-
sence of pruriginous lesions in abdomen and legs. In a
New Zealand study, the authors reviewed reports of
angioedema and urticaria associated with ACE inhibi-
tors. Of a total of 116 reports, 90% developed angioe-
dema or urticaria alone and 10% presented both
manifestations, without sex difference [11].
ACE inhibitors can cause non-immune, idiopatic
angioedematous and urticariform reactions, mediated by
complement system and others plasmatic systems. How-
ever, the exact mechanism for ACE inhibitors-induced
angioedema is not clear and it is still a matter of discus-
sion. Cyclo-oxygenase pathway activation, with masto-
cyte degranulation is described [12]. Some authors
attribute the ACE-inhibitor-related angioedema to the
increased levels of bradykinin [6,13,14] and substance P
[15]. The increased levels of bradykinin are not seen
with angiotensin II receptor blocker (ARB). However,
angioedema associated with ARB has also been
observed, although it is less common [16].
A study group proposed that ACE gene polymorphism
and some enzyme deficiencies could be involved in ACE
inhibitor-induced angioedema [5]. The amount of
Table 1 Drugs-related cutaneous reaction (Drugs widely prescribed for diabetic patients)
ACE Urticariform reactions (8;23); angioedema (8;23); bullous eruptions*(8;23); phototoxic reaction* (8;23); morbiliform eruption [24]
ARB Urticariform reactions; angioedema [22]
Acetylsalicylic Acid Urticaria [23]; angioedema [23]; Erythema polymorphous [24]
Thiazide Photosensitivity [23]; morbiliform eruption [24]
Insulin Papular Erythema [25]; urticaria [25]
Beta Blocker Drug induced lupus [24]; lichenoid eruption**[24]
*Only Captopril
**Only Propranolol
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immunoreactive ACE [17,18] and catalytic activity [19]
are related to I/D genetic polymorphism. In Chinese
patients there is evidence that genetic polymorphism is
associated with a structural alteration in ACE [19].
However, recent data showed no relationship between
ACE gene polymorphism and the occurrence of angioe-
dema with ACE and ARB [20]. One study analyzed the
metabolism of endogenous bradikinin (B2 receptor ago-
nist) and its active metabolite, des-Arg9-Bradikinin (B1
receptor agonist) in the presence of an ACE-inhibitor
during in vitro contact activation of plasma from hyper-
tensive patients who presented angioedema and these
kinetic parameters were compared with those measured
in a control group (without angioedema) of hypertensive
patients. They evidenced that the slope of bradikinin
degradation was lower in patients with angioedema,
such as des-Arg9-Bradikinin accumulation of the B1
agonist in these patients, when compared to controls,
suggesting that angioedema pathogenetic mechanism
lies in the catabolic site of kinin metabolism [21].
The presence of angioedema during treatment
requires the immediate cessation of treatment due to
the risk of possible severe complications [8]. If the drug
is not discontinued after the initial episode of angioe-
dema, a recurrence of episodes might occur [16]. In
patients who have experienced ACE inhibitor-related
angioedema, angiotensin receptor blockers should be
used cautiously [22]. Some consider its use contra-indi-
cated [8], but only a small percentage of patients with
ACE inhibitor-related angioedema continue with this
symptom when switched to an angiotensin II receptor
blocker. In the case of our patient, the prescription of
Losartan as nefroprotector did not result in any recur-
rent adverse effect.
Conclusion
We report a case of a black female diagnosed with type
1 diabetes that developed a clinical manifestation of
angioedema and drug reaction of early onset related to
the use of ramipril. The patient presented improvement
of the episode after substitution of the ACE inhibitor
and clinical treatment with oral anti-histamine and topic
corticosteroids and no recurrent symptoms after use of
losartan.
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